New research emanating from The Wistar Institute has illuminated a previously uncharacterized pathway by which a common dietary component, fructose, can actively promote the metastatic capabilities of certain cancer cells, particularly in aggressive forms of ovarian cancer. This groundbreaking study, detailed in the journal Nature Aging, uncovers a sophisticated communication mechanism employed by treatment-resistant cancer cells, enabling them to influence their neighbors and accelerate the spread of the disease. The findings suggest that residual cancer cells following therapeutic intervention are not merely dormant but can orchestrate a microenvironment conducive to tumor dissemination.
The research team identified fructose as a critical signaling molecule released by these resilient cancer cells that have survived chemotherapy. This discovery offers a novel perspective on how post-treatment cancer remnants can contribute to the systemic spread of malignant tumors. As Dr. Aidan Cole, a postdoctoral fellow at The Wistar Institute and the study’s lead author, explained, "While some cancer cells that endure chemotherapy may cease active division, they retain significant biological activity. Rather than proliferating, they persist in secreting molecules that transmit signals to adjacent cells. Our investigation stands as one of the pioneering efforts to demonstrate that a nutrient, specifically fructose in this instance, can function as one of these potent signaling agents."
Ovarian cancer frequently presents a formidable clinical challenge, characterized by a high propensity for recurrence and widespread dissemination. While most patients with ovarian cancer undergo treatment with platinum-based chemotherapy regimens, which often elicit a robust initial response, the malignancy typically returns. This resurgence is frequently accompanied by metastasis, the process where cancer cells spread from their primary site to distant parts of the body, predominantly throughout the abdominal cavity. Metastasis is the underlying cause of approximately 90% of cancer-related fatalities. Previous research had hinted that lingering cancer cells, those that evade initial therapeutic eradication, might play a pivotal role in disease recurrence by releasing a complex cocktail of molecular signals. To rigorously investigate this hypothesis, Dr. Cole and his collaborators designed an experimental paradigm that effectively isolated the substances secreted by surviving cancer cells from the cells themselves.
In their experimental setup, the researchers collected the molecules produced by chemotherapy-resistant cancer cells and then exposed other cancer cells to these collected substances. The results were striking: the mere presence of these secreted molecules was sufficient to significantly enhance the migratory and invasive potential of the exposed cancer cells. "To the best of our knowledge, this is the first demonstration, using a preclinical model rather than simply in vitro cell cultures, that it is the molecular entities released by these persistent cells, not the cells themselves, that are the primary drivers of cancer spread," Dr. Cole elaborated.
The subsequent phase of the investigation focused on pinpointing the specific released substance responsible for this pro-metastatic effect. Through meticulous analysis, the scientists determined that the surviving cancer cells were actively producing and utilizing fructose as a signal to stimulate the migratory behavior of nearby cancer cells. Furthermore, the study revealed that elevated levels of dietary fructose, comparable to those found in commonly consumed sugary beverages, could independently promote cancer spread, even in the absence of prior chemotherapy. This finding carries significant implications, suggesting that an individual’s dietary habits could potentially influence the progression of cancer.
This observation is particularly noteworthy given the widespread consumption of fructose in many parts of the world. In some populations, high-fructose corn syrup contributes a substantial proportion, estimated between 8-20%, of daily caloric intake. Unlike many established risk factors for cancer, which are often immutable, fructose consumption is amenable to modification through conscious dietary choices. While direct clinical trials investigating the impact of reduced fructose intake on patient outcomes have not yet been conducted, these findings strongly suggest that nutritional factors may exert an influence on cancer progression in ways that have been largely overlooked.
Delving deeper into the molecular mechanisms, the research team sought to understand precisely how fructose facilitates the escape and spread of cancer cells. Employing a suite of advanced analytical techniques, including a CRISPR screening approach, they uncovered a key metabolic effect: fructose appears to suppress cholesterol synthesis within neighboring cancer cells. Cholesterol plays a crucial role in maintaining the integrity of cellular structures, acting as a kind of biological adhesive that binds cells together. A reduction in cellular cholesterol levels consequently weakens these intercellular connections, rendering cancer cells more prone to detachment and subsequent migration to new locations within the body. This intricate mechanism provides a compelling explanation for how a ubiquitous nutrient can fundamentally alter the physical properties of tumor cells, thereby enhancing their capacity for dissemination.
The discovery that diminished cholesterol production might be a critical factor in promoting cancer spread also carries significant potential clinical relevance. Statins, a class of drugs widely prescribed to lower cholesterol levels and used by millions of individuals, operate by inhibiting cholesterol synthesis. Intriguingly, in the context of this study, statins alone demonstrated the ability to weaken the adhesive forces between cancer cells, making them more susceptible to detachment. This observation has prompted the researchers to explore whether these cholesterol-lowering medications could potentially interact with or interfere with the efficacy of chemotherapy. However, the research team has stressed that these findings should not be interpreted as a rationale for patients to discontinue any prescribed medications, including statins.
Dr. Katherine Aird, Professor and co-leader of the Molecular and Cellular Oncogenesis Program at The Wistar Institute and the study’s senior author, commented, "While we have not yet evaluated this effect in human patients, it certainly raises important questions regarding the potential synergistic or antagonistic effects of combining cholesterol-lowering drugs with chemotherapy. This is particularly relevant for ovarian cancer, which predominantly affects postmenopausal women who are often already taking statins."
The potential applicability of this fructose-related mechanism extends beyond ovarian cancer, prompting the researchers to investigate its role in other malignancies. "We hypothesize that other cancers that tend to spread within the trunk of the body, such as pancreatic, colon, and liver cancers, might exhibit similar behaviors. While we cannot definitively declare this phenomenon as universal at this stage, we believe the observed effects are not exclusively confined to ovarian cancer," stated Dr. Aird. Dr. Aird and Dr. Cole are currently initiating further studies to ascertain whether these findings can be replicated across a spectrum of different cancer types. The comprehensive list of co-authors and funding sources underscores the collaborative and multi-institutional nature of this significant research endeavor.
About the Author
